Bio­gen in­ves­ti­gates a death pos­si­bly linked to its con­tro­ver­sial new Alzheimer's drug

Bio­gen is in­ves­ti­gat­ing the death of a 75-year-old pa­tient po­ten­tial­ly linked to the com­pa­ny’s new Alzheimer’s drug, which the FDA con­tro­ver­sial­ly ap­proved via its ac­cel­er­at­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.